Bullish View on Clovis Oncology
Bullish view on Clovis Oncology as it breaks $30 price resistance.
CLVS jumped 13% last Wednesday as sales of its Rubraca drug used to treat ovarian cancer patients went up 33% compared to previous quarter.
CLVS jumped 13% last Wednesday as sales of its Rubraca drug used to treat ovarian cancer patients went up 33% compared to previous quarter.
免責聲明
這些資訊和出版物並不意味著也不構成TradingView提供或認可的金融、投資、交易或其他類型的意見或建議。請在使用條款閱讀更多資訊。